Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of empagliflozin on blood pressure, cardiovascular events, mortality and renal parameters in patients undergoing coronary artery bypass surgery
IRCT20190911044744N3Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in coronary arteriosclerosis, hypertension (HTN) and chronic kidney disease (CKD), sponsored by Shahid Sadoughi University of Medical Sciences. Primary endpoints: Blood pressure change, Cardiovascular events and 2 more. Started Jan 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
coronary arteriosclerosishypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20190911044744N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190911044744N3.